CYTOSORBENTS CORPORATION (NASDAQ:CTSO) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03
On June 4, 2019, at the 2019 Annual Meeting of Stockholders (the “Annual Meeting”) of CytoSorbents Corporation (the “Company”), the Company’s stockholders authorized the Company’s Board of Directors to amend and restate the Company’s First Amended and Restated Certificate of Incorporation to increase the total number of authorized shares of common stock of the Company from 50,000,000 shares to 100,000,000 shares and to increase the total number of authorized shares of capital stock of the Company from 55,000,000 shares to 105,000,000.
The Company filed its Second Amended and Restated Certificate of Incorporation (the “Restated Charter”) with the Secretary of State of the State of Delaware on June 12, 2019. The foregoing summary of the Restated Charter does not purport to be complete and is qualified in its entirety by reference to the full text of the Restated Charter, which is attached hereto as Exhibit 3.1 and incorporated herein by reference.
(d) The following Exhibit is submitted herewith.
| Exhibit No. | Description |
| 3.1 | Second Amended and Restated Certificate of Incorporation of CytoSorbents Corporation |
Cytosorbents Corp Exhibit
EX-3.1 2 tv523529_ex3-1.htm EXHIBIT 3.1 Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CYTOSORBENTS CORPORATION A Delaware Corporation CytoSorbents Corporation,…
To view the full exhibit click here
About CYTOSORBENTS CORPORATION (NASDAQ:CTSO)
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.
